133 related articles for article (PubMed ID: 1898982)
1. In vivo development and in vitro characterization of a subclone of murine P388 leukemia resistant to bis(diphenylphosphine)ethane.
Hoke GD; McCabe FL; Faucette LF; Bartus JO; Sung CM; Jensen BD; Heys JR; Rush GF; Alberts DW; Johnson RK
Mol Pharmacol; 1991 Jan; 39(1):90-7. PubMed ID: 1898982
[TBL] [Abstract][Full Text] [Related]
2. In vivo antitumor activity and in vitro cytotoxic properties of bis[1,2-bis(diphenylphosphino)ethane]gold(I) chloride.
Berners-Price SJ; Mirabelli CK; Johnson RK; Mattern MR; McCabe FL; Faucette LF; Sung CM; Mong SM; Sadler PJ; Crooke ST
Cancer Res; 1986 Nov; 46(11):5486-93. PubMed ID: 3756897
[TBL] [Abstract][Full Text] [Related]
3. Modulation of the antitumor and biochemical properties of bis(diphenylphosphine)ethane with metals.
Snyder RM; Mirabelli CK; Johnson RK; Sung CM; Faucette LF; McCabe FL; Zimmerman JP; Whitman M; Hempel JC; Crooke ST
Cancer Res; 1986 Oct; 46(10):5054-60. PubMed ID: 3756863
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of toxicity of an experimental bidentate phosphine gold complexed antineoplastic agent in isolated rat hepatocytes.
Smith PF; Hoke GD; Alberts DW; Bugelski PJ; Lupo S; Mirabelli CK; Rush GF
J Pharmacol Exp Ther; 1989 Jun; 249(3):944-50. PubMed ID: 2732955
[TBL] [Abstract][Full Text] [Related]
5. Characterization of four drug-resistant P388 sublines: resistance/sensitivity in vivo, resistance-and proliferation-markers, immunogenicity.
Fichtner I; Stein U; Hoffmann J; Winterfeld G; Pfeil D; Hentschel M
Anticancer Res; 1994; 14(5A):1995-2003. PubMed ID: 7847840
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists.
Yang JM; Goldenberg S; Gottesman MM; Hait WN
Cancer Res; 1994 Feb; 54(3):730-7. PubMed ID: 7905786
[TBL] [Abstract][Full Text] [Related]
7. A murine model to evaluate the ability of in vitro clonogenic assays to predict the response to tumors in vivo.
Mirabelli CK; Sung CM; McCabe FL; Faucette LF; Crooke ST; Johnson RK
Cancer Res; 1988 Oct; 48(19):5447-54. PubMed ID: 3046738
[TBL] [Abstract][Full Text] [Related]
8. Novel phosphonium salts display in vitro and in vivo cytotoxic activity against human ovarian cancer cell lines.
Manetta A; Gamboa G; Nasseri A; Podnos YD; Emma D; Dorion G; Rawlings L; Carpenter PM; Bustamante A; Patel J; Rideout D
Gynecol Oncol; 1996 Feb; 60(2):203-12. PubMed ID: 8631539
[TBL] [Abstract][Full Text] [Related]
9. In vitro multidrug resistance of P388 murine leukemia selected for resistance to diaziquone.
Gutierrez PL; Wilder PJ; Biswal N
Cancer Commun; 1989; 1(3):181-90. PubMed ID: 2576972
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function.
Per SR; Mattern MR; Mirabelli CK; Drake FH; Johnson RK; Crooke ST
Mol Pharmacol; 1987 Jul; 32(1):17-25. PubMed ID: 3037302
[TBL] [Abstract][Full Text] [Related]
11. Characterization of B16 melanoma cells resistant to the CC-1065 analogue U-71,184.
Moy BC; Petzold GL; Badiner GJ; Kelly RC; Aristoff PA; Adams EG; Li LH; Bhuyan BK
Cancer Res; 1990 Apr; 50(8):2485-92. PubMed ID: 2317831
[TBL] [Abstract][Full Text] [Related]
12. Cellular pharmacology of mu-[1,2-bis(diphenylphosphino)ethane]bis[(1-thio-beta-D-gluco pyranosato-S)gold(I)]: a novel antitumor agent.
Mirabelli CK; Jensen BD; Mattern MR; Sung CM; Mong SM; Hill DT; Dean SW; Schein PS; Johnson RK; Crooke ST
Anticancer Drug Des; 1986 Nov; 1(3):223-34. PubMed ID: 3450295
[TBL] [Abstract][Full Text] [Related]
13. Mitochondrial defects in cis-diamminedichloroplatinum(II)-resistant human ovarian carcinoma cells.
Andrews PA; Albright KD
Cancer Res; 1992 Apr; 52(7):1895-901. PubMed ID: 1551118
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of bis(diphenylphosphino)alkanes, their gold(I) coordination complexes, and related compounds.
Mirabelli CK; Hill DT; Faucette LF; McCabe FL; Girard GR; Bryan DB; Sutton BM; Bartus JO; Crooke ST; Johnson RK
J Med Chem; 1987 Dec; 30(12):2181-90. PubMed ID: 3681888
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of cytotoxicity of copper(I) complexes of 1,2-bis(diphenylphosphino)ethane.
Sanghamitra NJ; Phatak P; Das S; Samuelson AG; Somasundaram K
J Med Chem; 2005 Feb; 48(4):977-85. PubMed ID: 15715467
[TBL] [Abstract][Full Text] [Related]
16. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content.
Eng WK; McCabe FL; Tan KB; Mattern MR; Hofmann GA; Woessner RD; Hertzberg RP; Johnson RK
Mol Pharmacol; 1990 Oct; 38(4):471-80. PubMed ID: 2172765
[TBL] [Abstract][Full Text] [Related]
17. Characterization of multidrug resistance by fluorescent dyes.
Kessel D; Beck WT; Kukuruga D; Schulz V
Cancer Res; 1991 Sep; 51(17):4665-70. PubMed ID: 1873811
[TBL] [Abstract][Full Text] [Related]
18. Antitumor properties of some 2-[(dimethylamino)methyl]phenylgold(III) complexes.
Buckley RG; Elsome AM; Fricker SP; Henderson GR; Theobald BR; Parish RV; Howe BP; Kelland LR
J Med Chem; 1996 Dec; 39(26):5208-14. PubMed ID: 8978849
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of acquired resistance to methotrexate in P388 murine leukemia cells and in their doxorubicin-resistant subline.
Ramu N; Ramu A; Cole DE; Balis FM; Poplack DG; Pollard HB
Isr J Med Sci; 1988; 24(9-10):477-82. PubMed ID: 2974448
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the efficacy of a phenothiazine and a bisquinaldinium calmodulin antagonist against multidrug-resistant P388 cell lines.
Hait WN; Pierson NR
Cancer Res; 1990 Feb; 50(4):1165-9. PubMed ID: 2297765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
